Loading organizations...
§ Private Profile · South San Francisco, CA, USA
Spiral Therapeutics is a technology company.
Spiral Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapies for a range of inner ear disorders. The company employs a proprietary drug delivery platform engineered for the local, sustained delivery of therapeutic agents directly to the inner ear, bypassing systemic exposure. Its lead program, SPT-2101, is a sustained-release steroid formulation targeting conditions such as Meniere's disease, sensorineural hearing loss, and tinnitus.
The company was founded in 2016 by Hugo Peris, who also serves as its CEO. Peris established Spiral Therapeutics with the insight that many inner ear conditions lack effective and targeted treatment options, often requiring systemic drug administration with undesirable side effects. The mission was to address this unmet medical need by pioneering a novel approach to drug delivery for these delicate and difficult-to-access anatomical structures.
Spiral Therapeutics aims to serve patients suffering from acute and subacute hearing loss, Meniere's disease, and other balance disorders. The company’s long-term vision centers on transforming the treatment landscape for inner ear pathologies by providing precision therapies that restore and protect auditory and vestibular function, thereby significantly improving patient quality of life.
Spiral Therapeutics has raised $14.3M across 2 funding rounds.
Spiral Therapeutics has raised $14.3M in total across 2 funding rounds.
Spiral Therapeutics is a clinical-stage pharmaceutical company developing novel therapies for inner ear disorders, including hearing loss and balance issues like Meniere's Disease.[1][2][4] It builds a pipeline of advanced treatments using proprietary drug delivery technologies inspired by ophthalmology, targeting unmet needs in neurotology where no approved therapies exist; its lead product, SPT-2101, is a sustained-release steroid formulation for inner ear inflammation, delivered minimally invasively to the cochlea.[1][4][5] The company serves patients with conditions such as hearing loss and vertigo, solving problems of ineffective drug exposure in the inner ear through precise, durable administration; it has raised $8.3M across two funding rounds, with recent investment from Esperante Ventures and Ferring Ventures supporting expanded trials, and employs under 25 people in South San Francisco.[1][4]
Growth momentum includes completing enrollment in an open-label Australian trial for SPT-2101 showing safety, reduced vertigo, and superior pharmacokinetics, followed by a randomized placebo-controlled expansion; plans include an IND submission for US pivotal trials by late 2024 after acquiring Otonomy assets.[1][4]
Spiral Therapeutics was founded in early 2016 by Hugo Peris, Justin S. Hanes, and Eugene de Juan, drawing inspiration from ophthalmology to address inner ear challenges.[1][3] Headquartered in South San Francisco, the company launched with a focus on proprietary therapeutics and drug delivery for hearing loss, entering the clinic with lead candidate LPT99 (targeting APAF1 for hearing loss) in December 2018.[1][3] Pivotal early traction came from building a pipeline amid no approved treatments, recent funding to advance SPT-2101 (for Meniere's Disease), and asset acquisition from Otonomy, positioning it as a neurotology leader under CEO Hugo Peris.[3][4]
Spiral rides the wave of neurotology innovation, targeting inner ear disorders affecting millions amid aging populations and no FDA-approved local therapies, leveraging biotech advances in sustained-release delivery akin to ophthalmology successes.[1][2][4] Timing aligns with rising demand for non-surgical hearing/balance treatments, bolstered by post-pandemic focus on sensory health and M&A activity like Otonomy's assets enabling faster US trials.[4] Market forces include large unmet needs (e.g., Meniere's vertigo, sensorineural hearing loss) and investor interest in precision pharma platforms; Spiral influences the ecosystem by pioneering cochlear access, potentially unlocking a pipeline for balance/hearing disorders and inspiring similar drug-device hybrids.[1][3][5]
Spiral Therapeutics is poised to lead inner ear therapeutics, with SPT-2101's US pivotal trials via late-2024 IND submission as the key catalyst, potentially yielding first approvals in neurotology.[4] Trends like AI-optimized drug delivery, expanded gene therapies for hearing, and global trial acceleration will shape its path, amplifying influence through partnerships and pipeline growth (e.g., LPT99, BN-119).[3] As a nimble clinical-stage player with proven safety data, expect scaled funding, board expertise driving commercialization, and broader impact on protecting hearing—cementing its role from pipeline builder to market pioneer.[1][4]
Spiral Therapeutics has raised $14.3M across 2 funding rounds. Most recently, it raised $8.3M Other Equity in January 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 9, 2023 | $8.3M Venture Round | Catalio Capital, Savoir Capital | Humboldt Fund | Announced |
| Dec 1, 2018 | $6M Series A | Camden Partners, Savoir Capital | Catalio Capital, Sunghwan Choi, Inveready | Announced |
Spiral Therapeutics has raised $14.3M in total across 2 funding rounds.
Spiral Therapeutics's investors include Catalio Capital Management, Savoir Capital, Humboldt Fund, Camden Partners, Catalio Capital, Sunghwan Choi, Inveready.